151 related articles for article (PubMed ID: 32645153)
1. Inhibitors of the renin-angiotensin-aldosterone system and COVID-19 in critically ill elderly patients.
Jung C; Bruno RR; Wernly B; Joannidis M; Oeyen S; Zafeiridis T; Marsh B; Andersen FH; Moreno R; Fernandes AM; Artigas A; Pinto BB; Schefold J; Wolff G; Kelm M; De Lange DW; Guidet B; Flaatten H; Fjølner J;
Eur Heart J Cardiovasc Pharmacother; 2021 Jan; 7(1):76-77. PubMed ID: 32645153
[No Abstract] [Full Text] [Related]
2. COVID-19, hypertension, and renin-angiotensin-aldosterone system inhibitors: Much ado about nothing or real problem to be solved?
Tadic M; Cuspidi C
J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1984-1986. PubMed ID: 32951351
[No Abstract] [Full Text] [Related]
3. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
[No Abstract] [Full Text] [Related]
4. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.
Mancia G
Cardiovasc Res; 2020 Dec; 116(14):e198-e199. PubMed ID: 33245754
[No Abstract] [Full Text] [Related]
5. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
Palazzuoli A; Mancone M; De Ferrari GM; Forleo G; Secco GG; Ruocco GM; D'Ascenzo F; Monticone S; Paggi A; Vicenzi M; Palazzo AG; Landolina M; Taravelli E; Tavazzi G; Blasi F; Infusino F; Fedele F; De Rosa FG; Emmett M; Schussler JM; Tecson KM; McCullough PA
J Am Heart Assoc; 2020 Nov; 9(22):e017364. PubMed ID: 33023356
[TBL] [Abstract][Full Text] [Related]
6. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
Guo X; Zhu Y; Hong Y
Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694
[No Abstract] [Full Text] [Related]
7. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 effects on the renin-angiotensin-aldosterone system, therapeutic implications.
Ye Q; Lai EY; Luft FC; Persson PB; Mao J
Acta Physiol (Oxf); 2021 Apr; 231(4):e13608. PubMed ID: 33350096
[No Abstract] [Full Text] [Related]
9. Therapy With Agents Acting on the Renin-Angiotensin System and Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Gnavi R; Demaria M; Picariello R; Dalmasso M; Ricceri F; Costa G
Clin Infect Dis; 2020 Nov; 71(16):2291-2293. PubMed ID: 32442294
[TBL] [Abstract][Full Text] [Related]
10. COVID-19: The heart of the issue.
Woodward B; Kermali M
J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
[No Abstract] [Full Text] [Related]
11. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
Baral R; White M; Vassiliou VS
Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular disease and the impact of COVID-19.
Yoganathan A; Sajjad MS; Harky A
J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799
[No Abstract] [Full Text] [Related]
13. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality.
Stafford EG; Riviere JE; Xu X; Kawakami J; Wyckoff GJ; Jaberi-Douraki M
J Am Pharm Assoc (2003); 2020; 60(6):e145-e152. PubMed ID: 32561317
[TBL] [Abstract][Full Text] [Related]
14. The renin-angiotensin-aldosterone system inhibitors in COVID-19: from acidosis to ventilation and immunity.
Liao WH; Yang GG; Henneberg M
Swiss Med Wkly; 2020 Nov; 150():w20444. PubMed ID: 33306813
[No Abstract] [Full Text] [Related]
15. Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint.
Cappuccio FP; Siani A
Nutr Metab Cardiovasc Dis; 2020 Jul; 30(8):1227-1235. PubMed ID: 32595085
[TBL] [Abstract][Full Text] [Related]
16. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
17. ACE2: from protection of liver disease to propagation of COVID-19.
Warner FJ; Rajapaksha H; Shackel N; Herath CB
Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
[TBL] [Abstract][Full Text] [Related]
18. Re: Association of Inpatient Use of Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19.
Rouette J; Suissa K; Azoulay L
Epidemiology; 2020 Nov; 31(6):e52-e53. PubMed ID: 33555810
[No Abstract] [Full Text] [Related]
19. Assessment of ACE inhibitors/angiotensin receptor blockers in COVID-19 patients.
Sriram K; Insel PA
Am J Physiol Lung Cell Mol Physiol; 2020 Jul; 319(1):L37-L38. PubMed ID: 33496632
[No Abstract] [Full Text] [Related]
20. EMA advice on renin-angiotensin system medicines during covid-19 pandemic.
Drug Ther Bull; 2020 Jun; 58(6):85. PubMed ID: 32295811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
